Home / Health / India's Shilpa Medicare can make 100-200 million doses of Covid-19 shot

India's Shilpa Medicare can make 100-200 million doses of Covid-19 shot

The company's shares jumped as much as 9.2% on India's National Stock Exchange following the news

Reuters BENGALURU

1 min read Last Updated : Apr 07 2021 | 12:30 PM IST

By Sachin Ravikumar

BENGALURU (Reuters) - Indian drugmaker Shilpa Medicare Ltd has the production capacity to make 100-200 million doses of a recombinant vaccine for COVID-19, a company executive told Reuters on Wednesday.

The company's shares jumped as much as 9.2% on India's National Stock Exchange following the news.

(Reporting by Sachin Ravikumar in Bengaluru; Editing by Shounak Dasgupta)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)